Exhibit 99.2

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of July 1, 2022, is by and among Aztiq Pharma Partners S.à r.l., Aztiq Fund I SCSp, and Floki GP S.à r.l. (collectively, the "Filers").

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to the ordinary shares, with a nominal value of $0.01 per share, of Alvotech beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

Aztiq Pharma Partners S.à.r.l.		Aztiq Pharma Partners S.à.r.l.
By:	/s/ Danny Major	By:	/s/ Robert Wessman
Name: Danny Major		Name: Robert Wessman
Title: Manager		Title: Manager
Aztiq Fund I SCSp		Aztiq Fund I SCSp
By:	/s/ Danny Major	By:	/s/ Robert Wessman
Name: Danny Major		Name: Robert Wessman
Title: Manager of the general partner acting on behalf of the partnership		Title: Manager of the general partner acting on behalf of the partnership
Floki GP S.à r.l.		Floki GP S.à r.l.
By:	/s/ Danny Major	By:	/s/ Robert Wessman
Name: Danny Major Title: Manager		Name: Robert Wessman Title: Manager